[Renal Disorders and Drug Therapy].

In recent years, among patients treated with anticancer chemotherapy, the rate of chronic kidney disease has been increasing. Nephropathy is a major potential adverse event in cancer drug therapy. Anticancer chemotherapy, particularly in patients with comorbid chronic kidney disease, requires sufficient examination of the balance between the potential therapeutic benefit and the risk of decreased renal function. The overwhelming diversity of drugs used to treat cancer involves equally diverse nephropathy pathologies and dose adjustments. There is no established method for assessing renal function during cancer drug therapy. Although serum creatinine levels and eGFR are used to assess renal function in real-world clinical settings, they are generally recognized to be somewhat problematic, and there is currently no established method for assessing renal function before and after cancer drug therapy. When assessing renal function for adjusting anticancer drug doses, the Japanese eGFR is recommended. However, if the patient requires an adjustment of the anticancer drug dose, the renal functional assessment method that have used at the clinical trial have a high likelihood of being safe. In addition, despite the importance of the early diagnosis of acute kidney injury(AKI), currently, we cannot strongly recommend biomarker-based assessment for the early diagnosis of anticancer drug-induced AKI.